Vical gets patent for cytomegalovirus vax; Dutch gov't puts vaccines institute up for sale;

Vaccine Research

> Vical Incorporated has been issued the '112 patent covering DNA vaccines for cytomegalovirus containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant. Vical release

> Through a novel discovery approach, researchers at Children's Hospital Boston and Genocea Biosciences, in collaboration with the international nonprofit organization PATH, developed a new vaccine candidate that is potentially cheaper and able to protect against any pneumococcal strain. Children's Hospital Boston release

> Bangladesh is launching the world's largest trial of a cheap oral cholera vaccine, which could save tens of thousands of lives every year if it proves successful, health officials said. Story
 

Vaccine Market

> The Dutch government has put the production operations of its vaccines institute NVI up for sale at a time when large drugs firms are increasingly interested in acquiring vaccine makers. News

> A childhood vaccine against pneumonia-causing bacteria introduced in 2000 hasn't made a visible dent in the disease, U.S. researchers said Monday. Item

> With thousands of people either entering or leaving the UAE every day, a new online vaccination tracking system will be very handy, the Ministry of Health announced yesterday. Story

> India's plans to import and use a Bulgarian vaccine against the deadly Congo Hemorrhagic Fever virus (CCHF) might not prove very effective. Report

And Finally... Brian Deer radiates a remarkably bland persona for someone who stunned the global medical community and unravelled what he calls "one of those Aristotelian stories where you have both pity and fear." This is the journalist behind the series of stories that completely discredited the research linking the measles mumps rubella (MMR) vaccine to autism. Article

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.